SEC Form 4 · accession 0001470831-26-000569
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles J Homcy
Director
Period of report
Jun 20, 2026
Accepted (ET)
Jun 23, 2026 · 6:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 20, 2026 | F | 788 | $66.27 | D | 915,886 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs.